Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
110.450USD
+0.580+0.53%
Close 07-27 16:00（ET）Quotes delayed by 15 min
739.91MMarket Cap
LossP/E TTM
More Details of Monopar Therapeutics Inc Company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Monopar Therapeutics Inc Info
Ticker SymbolMNPR
Company nameMonopar Therapeutics Inc
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Number of employees16
Security typeOrdinary Share
Fiscal year-endDec 19
Address1000 Skokie Blvd Ste 350
CityWILMETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60091-1146
Phone18473880349
Websitehttps://www.monopartx.com/
Ticker SymbolMNPR
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Company Executives of Monopar Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
15.05K
-6.64%
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
162.08K
+5.42%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
15.05K
-6.64%
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
FAQs
Who are the top five shareholders of Monopar Therapeutics Inc?
The top five shareholders of Monopar Therapeutics Inc are: Dr. Chandler D. Robinson, M.D.
How many institutions hold shares of Monopar Therapeutics Inc (MNPR)?
As of 2026Q1, 147 institutions hold shares of Monopar Therapeutics Inc, with a combined market value of approximately 5.90M, accounting for 88.03% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1082274.00.